Regeneron Pumps $300M-Plus into Ocular Therapeutix for New Eylea Formulation
Thursday, October 13, 2016
Regeneron ($REGN) is investing hundreds of millions of dollars into troubled small cap Ocular Therapeutix ($OCUL) as it looks to develop a new form of its blockbuster eye drug Eylea (aflibercept).
Regeneron and Bedford, MA-based Ocular Therapeutix have signed a “strategic collaboration, option and license agreement” to work on a sustained-release formulation of the vascular endothelial growth factor (VEGF) trap med Eylea in wet AMD, as well as other retinal diseases.
Eylea is already approved in the U.S. and across global markets, where it is co-marketed with German pharma Bayer for a host of eye conditions, with wet AMD chief among them. Eylea made U.S. sales of $2.6 billion in 2015.
The med works by intravitreal (in the eye) injection every month initially, and then every other month in wet AMD, and typically continues as long as the patient needs it.